Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic castration-resistant prostate cancer (mCRPC) ...

Telix Pharmaceuticals recently reported completion of patient enrolment in its Phase 1 IPAX-2 study of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed at the ...

Leading particle accelerator company expands portfolio of positron emission tomography diagnostics LANSING, Mich., May 26, 2026 (GLOBE ...

Lantheus Holdings is back in focus after analysts lifted their fair value estimate from US$93.92 to US$104.08 per share. That change comes alongside generally constructive research coverage that leans ...

AbbVie (NYSE: ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha radiopharmaceuticals for cancer, today announced the abstract release for its oral presentation on ...

Extended pelvic lymph node dissection (ePLND) after radical prostatectomy failed to improve survival in intermediate- and ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that nine ...

Novartis announces new PSMAddition data shows 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer: Basel Tuesday, May 19, 2026, 16:00 H ...

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include ...

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, ...